Q301--Reference Laboratory Testing and Interpretation

SOURCES SOUGHT NOTICE This is a Sources Sought Notice (SSN) ONLY. The U.S. Government is conducting market research only to determine the availability of qualified sources capable of providing Reference Laboratory Testing and Interpretation services. Potential Contractors are invited to provide a response via e-mail to Contract Specialist at ross.byrne@va.gov by Sep 20, 2022 4:00 pm (PT). Responses will be used to determine the appropriate strategy for a potential acquisition. Please clearly identify any information your company considers sensitive or proprietary. This notice is issued solely for information and planning purposes - it does not constitute a Request for Quotation (RFQ), or a promise to issue an RFQ in the future. This notice does not commit the U.S. Government to contract for any supply or service. Further, the U.S. Government is not seeking quotes, or proposals at this time and will not accept unsolicited quotes in

response to this sources sought synopsis. The U.S. Government will not pay for any information or administrative costs incurred in response to this notice. Submittals will not be returned to the responder. Not responding to this notice does not preclude participation in any future RFQ, if any is issued. BACKGROUND: The Portland VA Medical Center, Portland Oregon, has a requirement for a Contractor to provide Reference Laboratory Testing and Interpretation services. Please see draft Statement of Work and the list of reference lab test below for requirements. NAICS: 621511 (Medical Laboratories) Interested potential Contractors please provide the following. 1) Company Name, address, point of contact, phone number, email address, and DUNS Please indicate business size: Small Disadvantage Business (SDB)____ 8(a)____ Historically Underutilized Business Zone (HUBZone)____ Service-Disabled Veteran-Owned Small Business (SDVOSB)____ Veteran-Owned Small Business (VOSB)_____ Economically Disadvantaged Women-Owned Small Business (EDWOSB)_____ Women-Owned Small Business concerns (WOSB)_____ Small Business_____ Large Business_____ Please state if you possess a Federal Supply Schedule (FSS)______. Please state if your FSS Schedule is under Group 66 III Cat 605-2A________ 2) Please submit a brief capability statement (Max one page) with enough information to demonstrate to the Veterans Affairs that you have the capability to provide the required reference lab testing and interpretation services as required in the attached draft Statement of Work. **Draft Statement of Work 1. Contract Title. Reference Laboratory Testing and Interpretation Services 2. Background. Reference and laboratory testing and interpretation services are required to support the Portland VA Medical Center. The Portland VA Path & Lab (PLMS) office utilizes the required lab testing and interpretation services in diagnosing and treating Veterans who are receiving medical care at the Portland VA Medical Center. 3. Period of Performance: See Price Schedule 4. Scope The Reference Laboratory shall provide in accordance with all applicable federal, state, and local regulations, laws, and ordinances, and in accordance with the specifications outlined for accreditation certification if applicable, patient specimen testing for the specific range of referral testing within their capability. Services shall include the performance of analytical testing as defined by the Laboratory's reference test manual, the reporting of analytical test results and consultative services as required. All requirements and provisions defined in the specifications of this solicitation will apply to any laboratory, i.e. branch, division, sub-contractor, etc. performing reference testing on behalf of the Reference Laboratory. The VA Facilities will be responsible for specimen collection and will provide laboratory specimens prepared according to the Reference Laboratory's user s manual, identified, and labeled for testing. 5. Specific Tasks. Reference Laboratory shall provide laboratory services to include: pre-analytic processing as defined in Reference Laboratory published user s manual; analysis, reporting of analytic results and interpretation of analytic clinical results. The number of tests requested under this contract will change throughout the life of the contract. The volumes or amounts shown in the solicitation are estimates only and impose no obligation on the VA. 6. Testing Methodology, Reference and Turn Around Time Routine test results shall be reported within the specified turnaround time (TAT) which is defined from time of specimen receipt by the contractor to when results are available. If testing is going to be delayed and the results will not be within published TAT, notify the VA Facilities of the new estimated TAT within 12 hours. Testing methodology and reference ranges for a test must be defined in the Reference Laboratory user manual and/or website. Reference Laboratory shall advise facility of any changes in methodology, procedure, reference ranges and any new tests introduced 30 days in advance. Reference Laboratory agrees to maintain the minimum acceptable service, reporting systems and quality control. Exception handling: Reference Laboratory will notify VA Facilities Laboratory Service within 24 hours of any problems with specimens received. The VA Facilities will provide laboratory specimens prepared according to the Reference Laboratory's user s manual, identified, and labeled for testing. Critical Value test results shall be reported immediately. Stat test results will be faxed or telephoned to Laboratory Service. Telephoned results will be confirmed with a follow-up by vendor via fax. The Reference Laboratory shall provide in accordance with all applicable federal, state, and local regulations, laws, and ordinances, and in accordance with the specifications outlined for accreditation certification if applicable, patient specimen testing for the tests listed in Section D. All requirements and provisions defined in the specification of this solicitation will apply to any laboratory, i.e. branch, division, sub-contractor, etc. performing reference testing on behalf of the Reference Laboratory. 7. DELIVERY AND REPORTING Results shall be faxed to PLMS PVAMC. Billing summaries shall begin the first day of the month and include the last day of the month. The Reference Laboratory shall provide a quarterly and end of year report showing sample issues, facility usage, and cost savings generated during the reporting period. The report will be due 45 days after the close of each government fiscal quarter. Invoicing: An itemized invoice shall accompany each service order from the Contractor. This invoice must show item number, description, quantity, unit, unit price, and totals for each design (advanced and basic) used. All invoices shall include contract number, purchase/delivery order number and detail of services provided. Invoicing: Invoices will be electronically submitted to the Tungsten website at http://www.tungstennetwork.com/uk/en/ Tungsten direct vendor support number is 877-489-6135 for VA contracts. The VA-FSC pays all associated transaction fees for VA orders. During Implementation (technical set-up) Tungsten will confirm your Tax Payer ID Number with the VA-FSC. This process can take up to 5 business days to complete to ensure your invoice is automatically routed to your Certifying Official for approval and payment. In order to successfully submit an invoice to VA-FSC please review How to Create an Invoice within the how to guides. All invoices submitted through Tungsten to the VA-FSC should mirror your current submission of Invoice, with the following items required. Clarification of additional requirements should be confirmed with your Certifying Official (your CO or buyer). The VA-FSC requires specific information in compliance with the Prompt Pay Act and Business Requirements: 1.) Your firm s Tax Payer ID number (TIN) Your firm s Remit Address information 3.) The VA Purchase Order (PO) number 4.) Your firm s contact information: (Personal Name, Email, and Phone) 5.) Your VA point of contact information: (Personal Name, Email, and Phone) 6.) The Period of Performance dates (Beginning and Ending) 7.) All discount information if applicable (Percent and Date Terms) For additional information, please contact: Tungsten Support Phone: 1-877-489-6135 Website: http://www.tungsten-network.com/uk/en/ Department of Veterans Affairs Financial Service Center Phone: 1-877-353-9791 Email: vafscched@va.gov Invoices shall be submitted monthly with the following information: 1.) Contract number and purchase order number 2.) Station ID (648) 3.) Date services were requested 4.) Patient name and test 5.) Invoice will be billed as individual line items as they are listed in the price schedule. Monthly invoice(s) will contain only those item numbers used for that month. Invoices not received in proper format will be returned. Marketing: Contractor shall not advertise or use any marketing material, logos, trade names, service marks, or other material belonging to the VA without consent. 8.Performance Monitoring: At the time of contract award the Contracting Officer will delegate a Contracting Officer Representative (COR) to assist with the contract monitoring requirements. The COR or designee will monitor such items as quality of service, contractor's ability to meet TAT's, correct billing, customer service, and review of the contractor's proficiency program. 9.LICENSING AND ACCREDITATION Reference Laboratory shall provide copies of all licenses, permits, accreditation and certificates required by law. Laboratory Director shall be a licensed American Board of Pathology certified pathologist or appropriately certified bio-analyst. All medical facilities providing laboratory services under the contract must possess a valid state license and meet JC standards as well as CLIA requirements and standards of the College of American Pathologists (CAP). 10.PERSONNEL The Reference Laboratory shall make sure all employees have current and valid professional certifications before starting work under this contract. The Reference Laboratory staff shall meet personnel qualifications required by Clinical Laboratory Improvement Act (CLIA) '88 Guidelines. The Government s reserves the right to request information or certification from the Contractor verifying they comply with this contract requirement. 11. Security Requirements. Not Applicable 12. Delivery and Pick-up Schedule. Deliver tests results from tests listed in Section D to the PLMS PVAMC via fax. Required Reference Laboratory Test Test ID Test Name _I099 Interphases, 25-99 (Bill Only) _I300 Interphases, >=100 (Bill Only) _IL25 Interphases, 25 (Bill Only) _PADD Probe, +1 (Bill Only) _PB02 Probe, +2 (Bill Only) _PB03 Probe, +3 (Bill Only) _PBCT Probe, +2 (Bill Only) _PRAH Probe, Each Additional (TLYM) (Bill Only) ACMFS AChR Modulating Flow Cytometry, Serum AGAW Alpha-Galactosidase, Leukocytes AGN1C Anti-Glial Nuclear Ab, Type 1, CSF AGN1S Anti-Glial/Neuronal Nuclear Antibody-Type 1 (AGNA-1), Serum AGNBC Antiglial/Neuronal Nuclear Antibody-Type 1, Immunoblot, Spinal Fluid AGNBS Antiglial/Neuronal Nuclear Antibody-Type,1 Immunoblot, Serum AINCC Alpha Internexin, Cell Binding Assay, Spinal Fluid AINCS Alpha Internexin, Cell Binding Assay, Serum AMIBC Amphiphysin Antibody, Immunoblot, Spinal Fluid AMIBS Amphiphysin Antibody, Immunoblot, Serum AMPCC AMPA-Receptor Antibody by CBA, Spinal Fluid AMPCS AMPA-Receptor Antibody by CBA, Serum AMPHC Amphiphysin Ab, CSF AMPIC AMPA-R Ab IF Titer Assay, CSF AMPIP Amyloid Protein Identification, Paraffin, LC-MS/MS AN1BC Antineuronal Nuclear Antibody-Type 1, Immunoblot, Spinal Fluid AN1BS Antineuronal Nuclear Antibody-Type 1, Immunoblot, Serum AN2BC Antineuronal Nuclear Antibody-Type 2, Immunoblot, Spinal Fluid AN2BS Antineuronal Nuclear Antibody-Type 2, Immunoblot, Serum ANN1C Anti-Neuronal Nuclear Ab, Type 1, CSF ANN1S Anti-Neuronal Nuclear Ab, Type 1, Serum ANN2C Anti-Neuronal Nuclear Ab, Type 2, CSF ANN2S Anti-Neuronal Nuclear Ab, Type 2, Serum ANN3C Anti-Neuronal Nuclear Ab, Type 3, CSF ANN3S Anti-Neuronal Nuclear Ab, Type 3, Serum ARSAW Arylsulfatase A, Leukocytes ATTRZ TTR Gene (Transthyretin-Associated Familial Amyloidosis), Full Gene Analysis BCRAB BCR/ABL1, p210, mRNA Detection, RT-PCR, Quantitative, Monitoring Chronic Myelogenous Leukemia (CML) CARBG Carbamazepine-10,11-Epoxide, Serum CARFT Carbamazepine, Free and Total, Serum CARTA Carbamazepine, Total, Serum CCPQ P/Q-Type Calcium Channel Ab, Serum COSPC Consult, Outside Slide (Bill Only) CRHPC Consult, w/Comp Rvw of His (Bill Only) CRMC CRMP-5-IgG, CSF CRMS CRMP-5 IgG, Serum CRMWS CRMP-5-IgG Western Blot, Serum CS2CC Contactin-Associated Protein-Like-2 (CASPR2)-IgG, Spinal Fluid CS2CS Contactin-Associated Protein-Like-2 (CASPR2)-IgG, Serum CSPPC Consult, w/Slide Prep (Bill Only) CUPPC Consult, w/USS Prof (Bill Only) DLAC D-Lactate, Plasma DLAU D-Lactate, Urine DPPCC Dipeptidyl-Peptidase-Like Protein-6 (DPPX) Antibody by Cell Binding Assay, Spinal Fluid DPPCS Dipeptidyl-Peptidase-Like Protein-6 (DPPX) Antibody by Cell Binding Assay, Serum DPPIC Dipeptidyl-Peptidase-Like Protein-6 (DPPX) Antibody by Immunofluorescence, Spinal Fluid DPPIS Dipeptidyl-Peptidase-Like Protein-6 (DPPX) Antibody by Immunofluorescence, Serum DPPTC Dipeptidyl-Peptidase-Like Protein-6 (DPPX) Antibody by Immunofluorescence Titer Assay, Spinal Fluid DPPTS Dipeptidyl-Peptidase-Like Protein-6 (DPPX) Antibody by Immunofluorescence Titer Assay, Serum EHRL Ehrlichia/Anaplasma, Molecular Detection, PCR, Blood ENC2 Encephalopathy, Autoimmune Evaluation, Spinal Fluid ENS2 Encephalopathy, Autoimmune Evaluation, Serum FQPPS Porphyrins, Feces GABCC GABA-B-Receptor Antibody by CBA, Spinal Fluid GABCS GABA-B-Receptor Antibody by CBA, Serum GABIC GABA-B-R Ab IF Titer Assay, CSF GABIS GABA-B-R Ab IF Titer Assay, Serum GANG Ganglionic Acetylcholine Receptor (Alpha3) Autoantibody, Serum GD65C Glutamic Acid Decarboxylase (GAD65) Antibody Assay, Spinal Fluid GD65S Glutamic Acid Decarboxylase (GAD65) Ab Assay, Serum GFACC Glial Fibrillary Acidic Protein Alpha Subunit Antibody, Cell Binding Assay, Spinal Fluid GFACS Glial Fibrillary Acidic Protein Alpha Subunit Antibody, Cell Binding Assay, Serum GFAIC Glial Fibrillary Acidic Protein Alpha Subunit Antibody, Immunofluorescence, Spinal Fluid GFAIS Glial Fibrillary Acidic Protein Alpha Subunit Antibody, Immunofluorescence, Serum GFATC Glial Fibrillary Acidic Protein Alpha Subunit Antibody, Immunofluorescence Titer Assay, Spinal Fluid GFATS Glial Fibrillary Acidic Protein Alpha Subunit Antibody, Immunofluorescence Titer Assay, Serum GL1CC Metabotropic Glutamate Receptor 1 (mGluR1) Antibody by Cell Binding Assay, Spinal Fluid GL1CS Metabotropic Glutamate Receptor 1 (mGluR1) Antibody by Cell Binding Assay, Serum GL1IC Metabotropic Glutamate Receptor 1 (mGluR1) Antibody by Immunofluorescence, Spinal Fluid GL1IS Metabotropic Glutamate Receptor 1 (mGluR1) Antibody by Immunofluorescence, Serum GL1TC Metabotropic Glutamate Receptor 1 (mGluR1) Antibody by Immunofluorescence Titer Assay, Spinal Fluid GL1TS Metabotropic Glutamate Receptor 1 (mGluR1) Antibody by Immunofluorescence Titer Assay, Serum GLYCC Glycine Receptor Alpha1 IgG, Cell Binding Assay, Spinal Fluid GLYCS Glycine Receptor Alpha1 IgG, Cell Binding Assay, Serum GRFCC GTPase Regulator Associated with Focal Adhesion Kinase pp125 Antibody, Cell Binding Assay, Spinal Fl GRFCS GTPase Regulator Associated with Focal Adhesion Kinase pp125 Antibody, Cell Binding Assay, Serum GRFIC GTPase Regulator Associated with Focal Adhesion Kinase pp125 Antibody, Immunofluorescence, Spinal Fl GRFIS GTPase Regulator Associated with Focal Adhesion Kinase pp125 Antibody, Immunofluorescence, Serum GRFTC GTPase Regulator Associated with Focal Adhesion Kinase pp125 Antibody, Immunofluorescence Titer Assa GRFTS GTPase Regulator Associated with Focal Adhesion Kinase pp125 Antibody, Immunofluorescence Titer Assa IFG23 Intact Fibroblast Growth Factor 23, Serum IG5CC IgLON Family Member 5 Antibody, Cell Binding Assay, Spinal Fluid IG5CS IgLON Family Member 5 Antibody, Cell Binding Assay, Serum IG5IC IgLON Family Member 5 Antibody, Immunofluorescence, Spinal Fluid IG5IS IgLON Family Member 5 Antibody, Immunofluorescence, Serum IG5TC IgLON Family Member 5 Antibody, Immunofluorescence Titer Assay, Spinal Fluid IG5TS IgLON Family Member 5 Antibody, Immunofluorescence Titer Assay, Serum IGATS IgG Asialo GM1 Titer, S IGDTS IgG Disialo GD1b Titer, S IGMTS IgG Monos GM1 Titer, S IHPCA IHC Additional Stain (Bill Only) IHPCI IHC Initial Stain (Bill Only) IMATS IgM Asialo GM1 Titer, S IMDTS IgM Disialo GD1b Titer, S IMMTS IgM Monos GM1 Titer, S ITPCC Inositol 1,4,5-Trisphosphate Receptor Type 1 Antibody, Cell Binding Assay, Spinal Fluid ITPCS Inositol 1,4,5-Trisphosphate Receptor Type 1 Antibody, Cell Binding Assay, Serum ITPIC Inositol 1,4,5-Trisphosphate Receptor Type 1 Antibody, Immunofluorescence, Spinal Fluid ITPIS Inositol 1,4,5-Trisphosphate Receptor Type 1 Antibody, Immunofluorescence, Serum ITPTC Inositol 1,4,5-Trisphosphate Receptor Type 1 Antibody, Immunofluorescence Titer Assay, Spinal Fluid ITPTS Inositol 1,4,5-Trisphosphate Receptor Type 1 Antibody, Immunofluorescence Titer Assay, Serum LG1CC Leucine-Rich Glioma Inactived Protein-1 (LGI1) IgG, Spinal Fluid LG1CS Leucine-Rich Glioma Inactivated Protein-1 (LGI1) IgG, Serum MESOF Mesothelioma, CDKN2A FISH, Tissue MLCPC Microdissection, Laser Capture (Bill Only) MOGFS Myelin Oligodendrocyte Glycoprotein (MOG-IgG1) Fluorescence-Activated Cell Sorting (FACS) Assay, Ser MSPTC Mass Spectrometry (Bill Only) NFHCC Neuronal Intermediate Filament Heavy Chain, Cell Binding Assay, Spinal Fluid NFHCS Neuronal Intermediate Filament Heavy Chain, Cell Binding Assay, Serum NFLCC Neuronal Intermediate Filament Light Chain, Cell Binding Assay, Spinal Fluid NFLCS Neuronal Intermediate Filament Light Chain, Cell Binding Assay, Serum NIFIC Neuronal Intermediate Filament IgG, Immunofluorescence, Spinal Fluid NIFIS Neuronal Intermediate Filament IgG, Immunofluorescence, Serum NIFTC Neuronal Intermediate Filament IgG, Immunofluorescence Titer Assay, Spinal Fluid NIFTS Neuronal Intermediate Filament IgG, Immunofluorescence Titer Assay, Serum NMDCC NMDA-Receptor Anitbody by CBA, Spinal Fluid NMDCS NMDA-R Ab CBA, Serum NMDIC NMDA-R Ab IF Titer Assay, CSF NMDIS NMDA-Receptor Antibody Titer Assay, Serum PAC1 Paraneoplastic Autoantibody Evaluation, Spinal Fluid PATHC Pathology Consultation PAVAL Paraneoplastic Autoantibody Evaluation, Serum PC1BC Purkinje Cell Cytoplasmic Antibody-Type 1, Immunoblot, Spinal Fluid PC1BS Purkinje Cell Cytoplasmic Antibody-Type 1, Immunoblot, Serum PCA1C Purkinje Cell Cytoplasmic Ab Type 1, CSF PCA2C Purkinje Cell Cytoplasmic Ab Type 2, CSF PCAB2 Purkinje Cell Cytoplasmic Ab Type 2, Serum PCABP Purkinje Cell Cytoplasmic Ab Type 1, Serum PCATR Purkinje Cell Cytoplasmic Ab Type Tr, Serum PCTBC Purkinje Cell Cytoplasmic Antibody-Type Tr, Immunoblot, Spinal Fluid PCTBS Purkinje Cell Cytoplasmic Antibody-Type Tr, Immunoblot, Serum PCTRC Purkinje Cell Cytoplasmic Ab Type Tr, CSF PIPA Pipecolic Acid, Serum PK1 Pyruvate Kinase Enzyme Activity, Blood PNEFC Neuroimmunology Antibody Follow-up, CSF PNEFS Neuroimmunology Antibody Follow-up, Serum REVE1 Erythrocytosis Evaluation, Whole Blood SGSU Synthetic Glucocorticoid Screen, Urine SRPBS Signal Recognition Particle Antibody Immunoblot, Serum SRPIS Signal Recognition Particle Antibody Screen, Immunofluorescence Assay, Serum SRPTS Signal Recognition Particle Antibody Titer, Immunofluorescence Assay, Serum SS2PC SpecStain, Grp II, Other (Bill Only) TLYM T-Cell Lymphoma, FISH, Tissue UPGD Uroporphyrinogen Decarboxylase (Upg D), Whole Blood VEGF Vascular Endothelial Growth Factor, Plasma VGKC Voltage-gated Potassium Channel Antibody, Serum VGKCC Neuronal Voltage-Gated Potassium Channel-Complex Autoantibody, Spinal Fluid ALDEF Alpha Defensin, Lateral Flow Assay, Synovial Fluid BPAB Bullous Pemphigoid, BP180 and BP230, IgG Antibodies, Serum D2F Fungal Sequencing Identification FUNA Fungal Ident Panel A FUNB Fungal Ident Panel B FUNID Culture, Fungus, Referred for Identification G145 Hereditary Custom Gene Panel Tier 1 (Bill Only) HEXBZ Sandhoff Disease, HEXB Gene, Full Gene Analysis, Varies LCCA Identification, Candida auris, Rapid PCR (Bill Only) LCCI Ident Rapid PCR Coccidioides (Bill Only) LCHB Id, Histoplasma/Blastomyces PCR (Bill Only) LCMAL Malaria Detection by Rapid PCR, Blood MOGFS Myelin Oligodendrocyte Glycoprotein (MOG-IgG1) Fluorescence-Activated Cell Sorting (FACS) Assay, Ser MOGTS Myelin Oligodendrocyte Glycoprotein (MOG-IgG-1) Fluorescence-Activated Cell Sorting (FACS) Titer Ass MTBXP Mycobacterium tuberculosis complex, Molecular Detection, PCR, Sputum NAGR Hexosaminidase A and Total, Leukocytes/Molecular Reflex, Whole Blood PBGD_ Porphobilinogen Deaminase (PBGD), Whole Blood PLA2R Phospholipase A2 Receptor Antibodies, Serum RMALF ID MALDI-TOF Mass Spec Fungi (Bill Only) RMALY ID MALDI-TOF Mass Spec Yeast (Bill Only) SFUNG (1, 3) Beta-D-Glucan (Fungitell), Serum TPPA Syphilis Antibody by TP-PA, Serum WARSQ Warfarin Response Genotype, Varies BRBPS Broad Range Bacterial PCR and Sequencing, Varies